Phase 3
Completed N=474
MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)
Source: ClinicalTrials.gov NCT00449956 ↗Enrolled (actual)
474
Serious AEs
—
Results posted
May 2009
Primary outcomePrimary: Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks — -2.50; -1.82; -2.78 mmHg
Summary
The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Intraocular Pressure (IOP) From Baseline at 8 Weeks |
-2.50; -1.82; -2.78 | — |
| SECONDARY Percent Change From Baseline in Intraocular Pressure (IOP) at 8 Weeks |
-11.99; -8.74; -13.46 | — |
| SECONDARY Percent Change From Baseline in Outflow Pressure Reduction Rate at 8 Weeks |
23.47; 17.17; 26.75 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with glaucoma and ocular hypertension
Exclusion Criteria
- History of ocular surgery within 3 months
- Administration contradiction to timolol and dorzolamide
Data sourced from ClinicalTrials.gov (NCT00449956). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.